78 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia and skin
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
may, among other things, include the Company's:
belief that chronic tendon injuries resulting from sports-related or occupational overuse … fails to provide a satisfactory solution to this chronic condition.
Treatment
The Company believes chronic tendon injuries resulting from sports-related
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
cellular deficits including chronic tendon injuries, androgenetic alopecia and skin aging.
The Company's corporate office and principal place
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
things, include the Company's:
belief that chronic tendon injuries resulting from sports-related or occupational overuse is a significant unmet medical … to provide a satisfactory solution to this chronic condition.
Treatment
The Company believes that chronic tendon injuries resulting from sports-related
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
presented in such statements or disclosures may, among other things, include the Company's:
belief that chronic tendon injuries resulting from sports … -
Treatment
The Company believes that chronic tendon injuries resulting from sports-related or occupational overuse is a significant unmet medical need
6-K
EX-99.1
vrgl2
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
xky7eyqdbihc4m
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.1
5hb24
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
tb7q0h26n
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
gtjfa1pwppd f37tpv
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.1
t0cgy
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.3
7n7df 4qk
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
tskr32w8avm
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
b9lahw
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
5j42rs4odoe3e a1565j
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
hl91a81k wtd80qzde
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
bkz3b 6y0
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.2
9on idjyq
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm